Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Agammaglobulinemia 1

Interventions

venetoclax 30Rituximab 24ibrutinib 22Cyclophosphamide 22acalabrutinib 21Specimen Handling 20obinutuzumab 17Biopsy 15fludarabine 13zanubrutinib 11pirtobrutinib 10fludarabine phosphate 10Magnetic Resonance Spectroscopy 9Bendamustine Hydrochloride 9Lenalidomide 7idelalisib 6Whole-Body Irradiation 6Mycophenolic Acid 6CT-P10 6ARQ531 6Cyclosporine 5Vincristine 4Sirolimus 4Prednisone 4Peripheral Blood Stem Cell Transplantation 4Doxorubicin 4Blood Component Removal 4pembrolizumab 3Tacrolimus 3Stem Cell Transplantation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × Panzyga × 90 days × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡